Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether the adoption of the RADAR dosing strategy could further reduce
treatment related toxicities improving the safety profile of niraparib.
Phase:
Phase 2
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Collaborators:
North Eastern German Society of Gynaecological Oncology North Eastern Germany Society of Gynaecologic Oncology